Cargando…
Asymmetric Dimethylarginine (ADMA) in Pediatric Renal Diseases: From Pathophysiological Phenomenon to Clinical Biomarker and Beyond
Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide (NO) synthase inhibitor, inhibits NO synthesis and contributes to the pathogenesis of many human diseases. In adults, ADMA has been identified as a biomarker for chronic kidney disease (CKD) progression and cardiovascular risk. However,...
Autores principales: | Hsu, Chien-Ning, Tain, You-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535118/ https://www.ncbi.nlm.nih.gov/pubmed/34682102 http://dx.doi.org/10.3390/children8100837 |
Ejemplares similares
-
Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA)
por: Tain, You-Lin, et al.
Publicado: (2017) -
Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes
por: Tsikas, Dimitrios, et al.
Publicado: (2018) -
Asymmetric Dimethylarginine (ADMA) and Endothelial Dysfunction: Implications for Atherogenesis
por: Landim, Maurício Batista Paes, et al.
Publicado: (2009) -
The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
por: Sibal, Latika, et al.
Publicado: (2010) -
Biological Functional Relevance of Asymmetric Dimethylarginine (ADMA) in Cardiovascular Disease
por: Franceschelli, Sara, et al.
Publicado: (2013)